Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT05587439
Status
Recruiting
Apply to this trial

Conditions

  • Genetic Disease
  • Genetic Predisposition
  • Hereditary Diseases
  • Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Data and Specimen Collection — GENETIC
    * Provide blood and/or saliva sample * Answer short questionnaires * Consider consenting to other optional parts of the research such as: * use stored tissue samples related to prior cancer treatment * Allow access to deceased relatives' medical records and stored specimens * Provide blood 1x per year for up to 5 years * Provide contact information of family members

Study Details

The purpose of this research study is to learn more about the inherited risk for developing lung cancer.

Key Dates

Start date
Jan 1, 2023
Status verified
Jul 2025
Primary completion
Nov 1, 2027
Completion
Nov 1, 2027

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Germline EGFR Mutations
    Individuals known to carry or at risk for carrying germline EGFR mutations (e.g., T790M, R776G/H/X, V769M, V834L, V843I, P848L, and others that will be identified). Patients with lung cancer with a somatic EGFR mutation prior to the initiation of treatment or who are found to have a suspected germline EGFR mutation via ctDNA analysis are also eligible.
  • Arm: Germline Non-EGFR Mutations
    Individuals known to carry or at risk for carrying non-EGFR germline mutations (e.g., HER2, BRCA2, MET, YAP1, and others that will be identified). Patients with lung cancer with a somatic variant suggestive of a possible hereditary lung cancer risk are also eligible.
  • Arm: Family History Or Multiple Primaries Or Multi-Focal Non-Small Cell Lung Cancer NSCLC
    Individuals and families with history of lung cancer where no pathogenic germline variant has been identified, but ascertained through history of one or more of the following: * Multi-generational or first-degree relative with lung cancer * Personal history of multiple primary lung cancers or other neoplasms * Multi-focal lung cancer

Primary Outcome Measure

Prevalence of rare germline EGFR mutations [ Time Frame: 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115
Jaclyn LoPiccolo, MD, PhD
[email protected]
617-632-6036
Jaclyn LoPiccolo, MD, PhD (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02115
Jaclyn LoPiccolo, MD, PhD
[email protected]
617-632-6036
Jaclyn LoPiccolo, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Brigham and Women's Hospital· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies